volume 5, issue 4, P364-370 2016
DOI: 10.21037/tcr.2016.07.12
View full text

Abstract: Even with recent advances in cancer diagnosis and therapy, treatment outcomes for many cancers remain dismal. Patients often show different response to the same therapy regimen, supporting the development of personalized medicine. 18F-FDG PET/CT has been used routinely in the assessment of tumor response, in prediction of outcomes, and in guiding personalized treatment. These assessments are mainly based on physician’s subjective or semi-quantitative evaluation. Recent development in Radiomics provides a prom…

expand abstract